Fidson Healthcare Plc delivered a blockbuster performance in the first quarter of 2025, posting a pre-tax profit of ₦4.8 billion, marking a 213.49% increase year-on-year from ₦1.5 billion in Q1 2024. The earnings surge was underpinned by rapid revenue expansion, powered largely by the company’s ethical product line.
Total revenue rose 85.42% year-on-year to ₦35 billion, up from ₦18.8 billion, with ethical drugs contributing ₦22.9 billion, followed by over-the-counter (OTC) products at ₦10.04 billion. The company’s aggressive market penetration and product mix strategy appear to be yielding significant returns.
Despite a 100.23% increase in cost of sales to ₦22.4 billion, Fidson maintained margin strength, with gross profit climbing 63.77% to ₦12.5 billion. Operating leverage was evident as the company scaled its top line.
Key Highlights:
- Revenue: ₦35 billion (+85.42% YoY)
- Gross Profit: ₦12.5 billion (+63.77% YoY)
- Operating Profit: ₦6.6 billion (+173.74% YoY)
- Pre-tax Profit: ₦4.8 billion (+213.49% YoY)
- Total Assets: ₦80.4 billion (+9.53% YoY)
- Retained Earnings: ₦20.9 billion (+18.32% YoY)
While administrative expenses jumped by 106.25% to ₦3.3 billion and selling and distribution costs rose 66.59% to ₦2.1 billion, the company’s operating profit still surged to ₦6.6 billion, reflecting efficient cost-to-revenue scaling.
The balance sheet remains robust with total assets increasing to ₦80.4 billion and retained earnings rising to ₦20.9 billion, further reinforcing shareholder value and Fidson’s long-term financial stability.
Conclusion:
Fidson Healthcare’s Q1 2025 performance reaffirms its strong position in Nigeria’s pharmaceutical market. With soaring ethical drug sales, disciplined operational execution, and a healthy balance sheet, the company appears well-positioned to sustain its growth trajectory despite rising cost pressures. Investors will be watching closely for continued momentum in the coming quarters.
How well do narratives help inform your perspective?
Disclaimer
The user WaneInvestmentHouse holds no position in NGSE:FIDSON. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.